Immunology remained active in this edition of Trial Watch, with attention moving toward stronger comparative trial designs. The clearest signal is the continued push in Crohn’s disease, where sponsors are working to prove not only efficacy, but clinical positioning against competitive mechanisms.
This suggests immunology development is entering a more mature phase where advantage, sequencing and differentiation matter as much as approval.